“Hypertriglyceridemia Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertriglyceridemia Market.
The Hypertriglyceridemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hypertriglyceridemia Pipeline Report:
Companies across the globe are diligently working toward developing novel Hypertriglyceridemia treatment therapies with a considerable amount of success over the years.
Hypertriglyceridemia companies working in the treatment market are Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others, are developing therapies for the Hypertriglyceridemia treatment
Emerging Hypertriglyceridemia therapies in the different phases of clinical trials are- LY3875383, TLC-2716, MAR001, ARO-APOC3, NST-1024, Olezarsen, Pegozafermin, and others are expected to have a significant impact on the Hypertriglyceridemia market in the coming years.
In May 2025, Ionis Pharmaceuticals reported positive topline results from the global Phase III Essence trial of Tryngolza (olezarsen) in individuals with moderate hypertriglyceridemia and/or at risk of atherosclerotic cardiovascular disease (ASCVD). Characterized by fasting triglyceride (TG) levels between ≥150mg/dL and <500mg/dL, the condition presents a significant cardiovascular risk. The randomized, multicenter, double-blind, placebo-controlled trial—conducted in partnership with the TIMI Study Group—evaluated the safety and efficacy of olezarsen in this target population.
In March 2025, Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical-stage biopharma company focused on developing novel biologics for metabolic and cancer-related diseases, has announced the completion of patient enrollment in its Phase 2 clinical trial of DR10624 for treating severe hypertriglyceridemia (SHTG). DR10624 is a first-in-class tri-specific agonist targeting FGF21R, GCGR, and GLP-1R. The randomized, double-blind, placebo-controlled study (“DR10624-201 study”) is assessing the safety and efficacy of three different dose levels of DR10624 in adults with SHTG, defined by fasting triglyceride levels ≥5.65 mmol/L (500 mg/dL). A total of 79 patients are participating in the 12-week trial.
Hypertriglyceridemia Overview
Hypertriglyceridemia is a condition characterized by high levels of triglycerides (a type of fat) in the blood. Triglycerides are produced from excess calories and are stored in fat cells. Elevated triglyceride levels can increase the risk of cardiovascular diseases, pancreatitis, and metabolic syndrome. Causes include obesity, diabetes, excessive alcohol intake, and genetic factors. It is typically managed through dietary changes, exercise, and medications.
Get a Free Sample PDF Report to know more about Hypertriglyceridemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight
Emerging Hypertriglyceridemia Drugs Under Different Phases of Clinical Development Include:
LY3875383: Eli Lilly and Company
TLC-2716: OrsoBio
MAR001: Marea Therapeutics
ARO-APOC3: Arrowhead Pharmaceuticals
NST-1024: NorthSea Therapeutics
Olezarsen: Ionis Pharmaceuticals
Pegozafermin: 89bio, Inc.
Hypertriglyceridemia Route of Administration
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Hypertriglyceridemia Molecule Type
Hypertriglyceridemia Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Hypertriglyceridemia Pipeline Therapeutics Assessment
Hypertriglyceridemia Assessment by Product Type
Hypertriglyceridemia By Stage and Product Type
Hypertriglyceridemia Assessment by Route of Administration
Hypertriglyceridemia By Stage and Route of Administration
Hypertriglyceridemia Assessment by Molecule Type
Hypertriglyceridemia by Stage and Molecule Type
DelveInsight’s Hypertriglyceridemia Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Hypertriglyceridemia product details are provided in the report. Download the Hypertriglyceridemia pipeline report to learn more about the emerging Hypertriglyceridemia therapies
Some of the key companies in the Hypertriglyceridemia Therapeutics Market include:
Key companies developing therapies for Hypertriglyceridemia are – Merck, Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer, AbbVie, Sanofi, GlaxoSmithKline, Biocon, Novo Nordisk, Tonghua Dongbao Pharmaceutical, Oramed Pharmaceuticals, and others.
Hypertriglyceridemia Pipeline Analysis:
The Hypertriglyceridemia pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hypertriglyceridemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertriglyceridemia Treatment.
Hypertriglyceridemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hypertriglyceridemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertriglyceridemia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hypertriglyceridemia drugs and therapies
Hypertriglyceridemia Pipeline Market Drivers
Increased Consumption of Unhealthy Diet, increase in research and developmental activities are some of the important factors that are fueling the Hypertriglyceridemia Market.
Hypertriglyceridemia Pipeline Market Barriers
However, high-cost associated with the disease, limited awareness about the disease and other factors are creating obstacles in the Hypertriglyceridemia Market growth.
Scope of Hypertriglyceridemia Pipeline Drug Insight
Coverage: Global
Key Hypertriglyceridemia Companies: Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others
Key Hypertriglyceridemia Therapies: LY3875383, TLC-2716, MAR001, ARO-APOC3, NST-1024, Olezarsen, Pegozafermin, and others
Hypertriglyceridemia Therapeutic Assessment: Hypertriglyceridemia current marketed and Hypertriglyceridemia emerging therapies
Hypertriglyceridemia Market Dynamics: Hypertriglyceridemia market drivers and Hypertriglyceridemia market barriers
Request for Sample PDF Report for Hypertriglyceridemia Pipeline Assessment and clinical trials
Table of Contents
1. Hypertriglyceridemia Report Introduction
2. Hypertriglyceridemia Executive Summary
3. Hypertriglyceridemia Overview
4. Hypertriglyceridemia- Analytical Perspective In-depth Commercial Assessment
5. Hypertriglyceridemia Pipeline Therapeutics
6. Hypertriglyceridemia Late Stage Products (Phase II/III)
7. Hypertriglyceridemia Mid Stage Products (Phase II)
8. Hypertriglyceridemia Early Stage Products (Phase I)
9. Hypertriglyceridemia Preclinical Stage Products
10. Hypertriglyceridemia Therapeutics Assessment
11. Hypertriglyceridemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypertriglyceridemia Key Companies
14. Hypertriglyceridemia Key Products
15. Hypertriglyceridemia Unmet Needs
16 . Hypertriglyceridemia Market Drivers and Barriers
17. Hypertriglyceridemia Future Perspectives and Conclusion
18. Hypertriglyceridemia Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
